TOS-358 is a covalent, pan-mutant, a-selective PI3K inhibitor designed to address key limitations of existing PI3Ka therapies which include ...

Celcuity plans to submit the data to the FDA as a supplemental new drug application. If everything goes to plan, the FDA will ...

OnKure Therapeutics, Inc. (OKUR) is gearing up for a major event in Q4 of 2024, which is that it intends to release data from its phase 1 PIKture-01 study using OKI-219 for the treatment of solid ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. The current PI3K 3C inhibitors in use in ...

PIKTOR is an investigational all-oral, multi-node inhibitor targeting escape routes in the PI3K/AKT/mTOR pathway that single-node inhibitors leave openBOSTON--(BUSINESS WIRE)--Sensei Biotherapeutics, ...

Celcuity's gedatolisib, a pan-PI3K/mTOR inhibitor for advanced breast cancer, shows strong early efficacy and is in pivotal Phase 3 trials, yet remains undervalued. The company has a healthy cash ...

TOS-358 is a covalent, pan-mutant, α-specific PI3K inhibitor designed to address key limitations of existing PI3Kα therapies which include ...

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. There are several clinical trials that are ...

HOUSTON -- Two-thirds of patients with PI3K-mutant brain metastases responded to the maximum tolerated dose (MTD) of the small-molecule inhibitor paxalisib plus radiation therapy (RT), a small phase I ...